AI model predicts treatment response in esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether an artificial intelligence (AI) model can accurately predict if esophageal cancer will completely disappear after chemotherapy combined with immunotherapy before surgery. If successful, it could help doctors decide the best treatment plan for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of esophageal squamous cell carcinoma (a specific type of esophageal cancer).
- You must have received at least one round of chemotherapy combined with immunotherapy before surgery (neoadjuvant treatment).
- You must have had a CT scan with contrast dye before starting neoadjuvant treatment.
- You must have had a CT scan with contrast dye after finishing neoadjuvant treatment and before surgery.
- You cannot have had any other cancer or received any other anti-cancer treatments before or during this neoadjuvant therapy.
- Your medical records must be complete, and your CT images must be of good quality.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a combination of imaging and clinical data to see if a computer model can predict how well your treatment will work. It aims to help doctors better understand your cancer risk and choose the best treatment plan for you.
This trial uses artificial intelligence to analyze CT scans and predict how well esophageal cancer responds to chemotherapy combined with immunotherapy before surgery. The goal is to help doctors personalize treatment for better outcomes.
This trial uses artificial intelligence (AI) to help plan personalized treatment for esophageal cancer by combining images and tissue samples. It aims to improve care by guiding doctors to choose the best therapy for each person.
This trial uses artificial intelligence to analyze CT scans, blood, and tumor tissue to predict how well your cancer will respond to chemotherapy and immunotherapy before surgery. It aims to personalize treatment for locally advanced stomach or gastroesophageal junction cancer.
This trial uses artificial intelligence to create a digital twin of your cancer and simulate how it might respond to treatment. It aims to personalize your care and improve outcomes for people with locally advanced esophageal cancer.
This trial tests if artificial intelligence can help doctors more accurately determine how deep early esophageal cancer goes during an endoscopic ultrasound. It may lead to better treatment decisions for people with early signs of esophageal cancer.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.